Medirom Healthcare to Introduce New Treasury Strategy Utilizing Cryptocurrency
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 29 2025
0mins
New Treasury Strategy: MEDIROM Healthcare Technologies has launched a treasury strategy that includes holding Worldcoin (WLD) as a reserve asset to diversify business activities and reduce financial risks.
WLD Holdings: As of October 28, 2025, the company holds 6,840 WLD, which will be utilized through their MOTHER Bracelet, a smart tracker that does not require charging.
Incentive Program: The company plans to distribute WLD as incentives to users with specific medical conditions who provide vital data using the MOTHER Bracelet.
Data Collection Goal: This incentive program aims to gather vital data from a larger patient population to enhance healthcare insights and services.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRM
About MRM
Medirom Healthcare Technologies Inc is a Japan-based holistic health services provider. The Company is a franchiser and operator of healthcare salons across Japan and is a preferred platform partner for large consumer brands, healthcare service providers and government entities. The Company mainly operates in two business segments. The Relaxation Salon Segment is engaged in the development of relaxation studios nationwide, centered on Re.Ra.Ku for the purpose of health management services. The Digital Preventative Healthcare Segment is involved in the sampling business, which includes brand promotion and consumer analysis for third party brands of corporate clients, government-sponsored specific health guidance program, utilizing internally-developed on-demand health monitoring smartphone application Lav, as well as MOTHER Tracker for fitness applications, and preventative healthcare services utilizing digital application and devices.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Micromem Technologies Closes C$327,778 Private Placement
- Successful Private Placement: Micromem Technologies has closed a non-brokered private placement, raising approximately C$327,778 by issuing 6,555,555 units at C$0.05 each, indicating market confidence in its financing needs.
- Clear Use of Proceeds: The funds raised will be allocated for working capital, reflecting Micromem's strategic intent to enhance its intelligent application development capabilities, particularly in sectors like oil & gas and healthcare.
- Compliance Requirements: The securities issued are subject to post-closing compliance requirements from the Canadian Securities Exchange, ensuring the company operates within legal frameworks and bolstering investor confidence.
- Future Financing Potential: Micromem may close an additional tranche of up to C$167,000 as needed, demonstrating the company's proactive planning for future capital requirements to further support its business growth.
Continue Reading
MRM Health Receives FDA Clearance to Initiate MH002 Clinical Trial
- Clinical Trial Launch: MRM Health's MH002 program has received FDA clearance, marking the initiation of the STARFISH-UC Phase 2b clinical trial, which is expected to enroll approximately 204 patients with mild-to-moderate ulcerative colitis, advancing the development of next-generation therapies for inflammatory bowel diseases.
- Efficacy Validation: MH002 demonstrated excellent safety and encouraging efficacy in its Phase 2a trial, with significant mucosal healing and anti-inflammatory effects observed after 8 weeks of treatment, laying a solid foundation for the upcoming Phase 2b trial.
- Innovative Technology Platform: MH002 is designed and manufactured using MRM Health's CORAL® platform, ensuring drug consistency and high quality, which supports cost-effective treatments for chronic inflammatory conditions and holds significant market potential.
- Funding Support: MRM Health successfully closed a €55 million Series B round in September 2025, enhancing its R&D capabilities in inflammatory diseases and providing financial backing for future clinical advancements.
Continue Reading